公开(公告)号：WO2003086305A3

公开(公告)日：2003-10-23

申请号：PCT/US2003/011061

申请日：2003-04-10

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  SCHWARTZ, Daniel M. ,  DUNCAN, Keith ,  STEWART, Jay

Inventor： SCHWARTZ, Daniel M. ,  DUNCAN, Keith ,  STEWART, Jay

IPC: A61K47/30

Abstract: The present invention relates to methods and pharmaceutical compositions involving the use of bioerodible (biodegradable) polymers to address fundamental needs in ocular surgery including sealants and sealing methods, barriers to cellular adhesion and proliferation, and mechanical barriers. In a particular embodiment, the present invention is also directed to the treatment of intraocular hypotony in an eye by limiting the flow of aqueous from the eye. In a preferred embodiment, application of a polymer, such as to the angle of the eye, limits the flow, thereby increasing the intraocular pressure.

公开(公告)号：WO2006039551A2

公开(公告)日：2006-04-13

申请号：PCT/US2005035294

申请日：2005-09-30

Applicant: UNIV CALIFORNIA ,  CALIFORNIA INST OF TECHN ,  DAVIS MARK E ,  SCHWARTZ DANIEL M

Inventor： DAVIS MARK E ,  SCHWARTZ DANIEL M

IPC: A61K31/724 ,  A61K31/203

CPC classification number: A61K31/203 ,  A61K31/724

Abstract: The present invention relates to improving, at least in part, a deficiency in dark adaptation for an individual. The therapy for dark adaptation includes local administration of a retinoid, such as a Vitamin A or a derivative thereof, such that deleterious side effects seen with systemic administration are avoided.

Abstract translation: 本发明涉及至少部分地改善个体暗适应性的缺陷。 暗适应疗法包括局部施用类维生素A，例如维生素A或其衍生物，从而避免全身施用所见的有害副作用。

公开(公告)号：WO2005091909A2

公开(公告)日：2005-10-06

申请号：PCT/US2005/006554

申请日：2005-03-01

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  SCHWARTZ, Daniel, M. ,  DUNCAN, Keith, G. ,  BAILEY, Kathy, R. ,  KANE, John ,  ISHIDA, Brian, Y.

Inventor： SCHWARTZ, Daniel, M. ,  DUNCAN, Keith, G. ,  BAILEY, Kathy, R. ,  KANE, John ,  ISHIDA, Brian, Y.

IPC: A61K31/56 ,  A61K31/66 ,  A61K38/17

CPC classification number: A61K31/685 ,  A61K31/66 ,  A61K38/17 ,  A61K38/1709 ,  A61K2300/00

Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced by delivering Apolipoprotein A1, particularly a mimetic peptide.

Abstract translation: 本发明通过调节与动脉粥样硬化相似的致病机制来解决年龄相关性黄斑变性的治疗。 在另外的具体实施方案中，增加反向胆固醇转运的组合物被用作年龄相关性黄斑变性的治疗靶标。 在一个具体的实施方案中，通过递送载脂蛋白A1，特别是模拟肽来减少视网膜色素上皮和/或Bruch's膜的脂质含量。

公开(公告)号：WO2005072223A2

公开(公告)日：2005-08-11

申请号：PCT/US2005/001773

申请日：2005-01-21

Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY ,  TIRRELL, David, A. ,  SCHWARTZ, Daniel, M. ,  NOWATZKI, Paul, J. ,  GRUBBS, Robert, H.

Inventor： TIRRELL, David, A. ,  SCHWARTZ, Daniel, M. ,  NOWATZKI, Paul, J. ,  GRUBBS, Robert, H.

IPC: A61F2/14 ,  A61F2/16 ,  A61K9/00 ,  A61L27/22 ,  A61L27/34 ,  C07K14/78 ,  C12N15/00

CPC classification number: C07K14/78 ,  A01K2217/05 ,  A01K2227/105 ,  A61F9/007 ,  A61L27/227 ,  A61L27/34 ,  A61L2430/16 ,  C07K2319/20 ,  C07K2319/21 ,  G02C7/02 ,  C08L89/00

Abstract: The present invention provides engineered proteins and biomedical products made from the engineered proteins. The biomedical products include lenses useful for ophthalmic purposes.

Abstract translation: 本发明提供了由工程蛋白质制成的工程化蛋白质和生物医学产品。 生物医学产品包括可用于眼科用途的镜片。

公开(公告)号：WO2004098506A2

公开(公告)日：2004-11-18

申请号：PCT/US2004013332

申请日：2004-04-30

Applicant: UNIV CALIFORNIA ,  SCHWARTZ DANIEL M ,  DUNCAN KEITH G ,  BAILEY KATHY R ,  KANE JOHN ,  ISHIDA BRIAN Y

Inventor： SCHWARTZ DANIEL M ,  DUNCAN KEITH G ,  BAILEY KATHY R ,  KANE JOHN ,  ISHIDA BRIAN Y

IPC: A61K20060101 ,  A61K31/00 ,  A61K31/192 ,  A61K31/198 ,  A61K31/203 ,  A61K31/381 ,  A61K31/56 ,  A61K31/575 ,  A61K31/58 ,  A61K

CPC classification number: A61K31/20 ,  A61K31/00 ,  A61K31/192 ,  A61K31/198 ,  A61K31/203 ,  A61K31/381 ,  A61K31/56 ,  A61K31/575 ,  A61K31/58

Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

Abstract translation: 本发明通过调节与动脉粥样硬化相似的致病机制来解决年龄相关性黄斑变性的治疗。 在进一步的具体实施方案中，使用反向胆固醇转运组分如转运蛋白和HDL级分作为年龄相关性黄斑变性的诊断和治疗靶标。 在一个具体实施方案中，视网膜色素上皮和/或Bruch's膜的脂质含量降低。

公开(公告)号：WO2003049685A3

公开(公告)日：2003-06-19

申请号：PCT/US2002/038856

申请日：2002-12-06

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  SCHWARTZ, Daniel, M. ,  DUNCAN, Keith ,  BAILEY, Kathy ,  KANE, John ,  ISHIDA, Brian

Inventor： SCHWARTZ, Daniel, M. ,  DUNCAN, Keith ,  BAILEY, Kathy ,  KANE, John ,  ISHIDA, Brian

IPC: A61K31/195

Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid) content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

公开(公告)号：WO2004004757A8

公开(公告)日：2004-10-07

申请号：PCT/US0320672

申请日：2003-07-01

Applicant: UNIV CALIFORNIA ,  CALIFORNIA INST OF TECHN ,  SCHWARTZ DANIEL M ,  FRASER SCOTT ,  GRUBBS ROBERT H ,  GALLIVAN JUSTIN P ,  YU C J

Inventor： SCHWARTZ DANIEL M ,  FRASER SCOTT ,  GRUBBS ROBERT H ,  GALLIVAN JUSTIN P ,  YU C J

IPC: G01N21/64 ,  A61B3/12 ,  A61F9/007 ,  A61K9/127 ,  A61K38/46 ,  A61K38/48 ,  A61K41/00 ,  A61K45/00 ,  A61K47/48 ,  A61K49/00 ,  A61P27/02 ,  A61P27/06 ,  G01N21/17 ,  A61K38/43

CPC classification number: A61K49/0056 ,  A61K38/482 ,  A61K41/00 ,  A61K49/0017

Abstract: The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.

Abstract translation: 本发明涉及改变眼睛中至少一个组织的至少一部分的物理和/或化学性质。 在具体实施方案中，它涉及任何眼睛疾病的治疗，尽管在具体实施方案中个体具有增厚的布鲁赫氏膜。 使用活化能源来实现Bruch膜的受控扩散增强和/或降解，其能够改善脉络膜和视网膜之间的扩散转运。 给个体施用与膜相关的失活的扩散增强分子，然后将其精确地暴露于活化能源，例如光或超声波。

公开(公告)号：WO2003049685A2

公开(公告)日：2003-06-19

申请号：PCT/US2002/038856

申请日：2002-12-06

Applicant: SCHWARTZ, Daniel M. ,  DUNCAN, Keith ,  BAILEY, Kathy ,  KANE, John ,  ISHIDA, Brian

Inventor： SCHWARTZ, Daniel M. ,  DUNCAN, Keith ,  BAILEY, Kathy ,  KANE, John ,  ISHIDA, Brian

IPC: A61K

CPC classification number: A61K31/198 ,  A61K31/00 ,  A61K31/192 ,  A61K31/203 ,  A61K31/381 ,  A61K31/56 ,  A61K31/575 ,  A61K31/58

Abstract: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid) content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

Abstract translation: 本发明通过调节与动脉粥样硬化相似的致病机制来解决年龄相关性黄斑变性的治疗。 在进一步的具体实施方案中，使用反向胆固醇转运组分如转运蛋白和HDL级分作为年龄相关性黄斑变性的诊断和治疗靶标。 在具体实施方案中，视网膜色素上皮细胞和/或Bruch膜的脂质含量降低。

公开(公告)号：WO02076338A3

公开(公告)日：2003-04-17

申请号：PCT/US0208674

申请日：2002-03-21

Applicant: CALHOUN VISION ,  JETHMALANI JAGDISH M ,  CHANG SHIAO H ,  GRUBBS ROBERT H ,  KORNFIELD JULIA A ,  SCHWARTZ DANIEL M ,  SANDSTEDT CHRISTIAN A ,  CHRIST F RICHARD

Inventor： JETHMALANI JAGDISH M ,  CHANG SHIAO H ,  GRUBBS ROBERT H ,  KORNFIELD JULIA A ,  SCHWARTZ DANIEL M ,  SANDSTEDT CHRISTIAN A ,  CHRIST F RICHARD

IPC: A61L27/00 ,  A61F2/16 ,  B29D11/00

CPC classification number: A61F2/16 ,  A61F2/1613 ,  A61F2/1616 ,  A61F2/1627 ,  A61F2/1635 ,  A61F2002/1699 ,  A61L27/14 ,  A61L27/50 ,  A61L2430/16 ,  B29D11/00009 ,  B29D11/00355 ,  B29D11/023 ,  G02C7/02 ,  G02C2202/14

Abstract: The present invention (Figure 1) relates to a method for creating shaped implants, such as intraocular lenses in vivo, as well as the novel implants themselves. Utilizing the method of the invention, it is possible to create an implant in vivo and to adjust either the physical properties such as refractive index, viscosity, etc., mechanical properties such as modulus, tensile strength, tear, etc., or the shape of the implant by noninvasive means. For example, using the method of the patent it is possible to create an intraocular lens in vivo and then adjust the shape and power of the lens through no invasion means. The novel implants are also addressed in this application.

Abstract translation: 本发明（图1）涉及用于产生成形植入物的方法，例如体内的眼内透镜，以及新颖的植入物本身。 利用本发明的方法，可以在体内产生植入物，并且可以调节诸如折射率，粘度等的物理性质，模量，拉伸强度，撕裂等的机械性能或形状 的植入物通过无创手段。 例如，使用该专利的方法，可以在体内产生眼内透镜，然后通过无侵入手段来调整透镜的形状和功率。 本申请中还提到了新颖的植入物。

公开(公告)号：WO2003011194A1

公开(公告)日：2003-02-13

申请号：PCT/US2002/023623

申请日：2002-07-26

Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY ,  UNIVERSITY OF CALIFORNIA, SAN FRANCISCO ,  JETHMALANI, Jagdish, M. ,  MALONEY, Robert, K. ,  GRUBBS, Robert, H. ,  KORNFIELD, Julia, A. ,  SANDSTEDT, Christian, A. ,  SCHWARTZ, Daniel, M.

Inventor： JETHMALANI, Jagdish, M. ,  MALONEY, Robert, K. ,  GRUBBS, Robert, H. ,  KORNFIELD, Julia, A. ,  SANDSTEDT, Christian, A. ,  SCHWARTZ, Daniel, M.

IPC: A61F2/16

CPC classification number: A61F2/14 ,  A61F2/16

Abstract: A method for evaluating the effectiveness of adjustable optical implants is provided. The implants are first inserted into a test subject. The implant is then exposed to an external stimulus, such as light, to induce a change in the properties of the implant. The implants are then evaluated to determine the nature and extent of the change in properties.

Abstract translation: 提供了一种用于评估可调节光学植入物的有效性的方法。 首先将植入物插入测试对象。 然后将植入物暴露于诸如光的外部刺激，以引起植入物的性质的改变。 然后评估植入物以确定性质变化的性质和程度。